Subscribe to FierceBiotech to get industry news and updates delivered to your inbox. Last month, Spark signed a licensing deal with Pfizer Inc. for continued research and development of a gene-based treatment for hemophilia B. Spark Therapeutics is getting a new CMO from their new owners. Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. Meanwhile, 2014's record-setting pace of biotech IPOs has hardly slowed in the new year, as this week alone has seen Ascendis Pharma ($ASND) raise $108 million, Flex Pharma ($FLKS) bank $86 million and Zosano Pharma ($ZSAN) pull in $50 million. The company, headquartered in Philadelphia, sold 7 million shares at $23 apiece, a price roughly 35% above the high end of its initial range. And gene therapy as a whole is in the midst of a second honeymoon among investors and researchers. 2017-08-02: EX-99.1 According to the SEC filing, Children's holds 53.44 percent of Spark shares. Shares of Spark Therapeutics Inc more than doubled in their debut, valuing the gene-therapy company at nearly $1.5 billion and underscoring investor's interest in … PHILADELPHIA, Jan. 30, 2015 /PRNewswire/ — Spark Therapeutics announced today the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. Spark Therapeutics co-founder Dr. Katherine High is leaving the Philadelphia gene therapy company after seven years leading its groundbreaking product development activities. Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. The total value of the deal is $4.8 billion. That deal gives Spark $20 million up front, up to $260 million in milestone payments, and royalties based on net sales. Spark Therapeutics has raised a total of $122.8M in funding over 2 rounds. Spark Therapeutics Raises $72.8 Million in Oversubscribed Financing Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 … The boards of … Spark has earmarked most of its potential proceeds for SPK-RPE65, an FDA-designated "breakthrough" therapy now in Phase III development to treat a group of vision-destroying ailments called inherited retinal dystrophies. In May, Spark collected $72.7 million in a second round of financing. That money, combined with its IPO haul, should fund its work through 2017, Spark said, paying the way for its clinical candidates and helping get some early-stage assets into Phase I. The ticker symbol refers to the hope Spark's medicine will cure, not simply treat, some genetic diseases, including types of blindness and hemophilia. Spark Therapeutics is registered under the ticker NASDAQ:ONCE . We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Children's CEO Steven Altschuler is chairman of the board of Spark. Spark Therapeutics Inc., which hopes to turn decades of gene-therapy research at Children's Hospital of Philadelphia into commercial cures for diseases, has filed papers to conduct an initial public stock offering. (?Spark?) The company belongs in the Biotechnology industry, Healthcare sector and employs 368 people. Covering the IPO market from A to Z. All rights reserved. After launching in late 2013 with $50 million and a clutch of gene therapies out of Children’s Hospital of Philadelphia, Spark Therapeutics hit the gas. View real-time stock prices and stock quotes for a full financial overview. 3 Speen Street, Suite 300, Framingham, MA 01701. Special Report: FierceBiotech's 2014 Fierce 15 - Spark Therapeutics, © 2021 Questex LLC. And that's drawn the attention of heavyweights including Pfizer, Biogen Idec ($BIIB), Celgene ($CELG) and Bayer. Spark Therapeutics, Inc.ONCE announced that the European Commission ("EC") has approved the marketing authorization application ("MAA") for its gene therapy, Luxturna (voretigene neparvovec). Spark Therapeutics is funded by 7 investors. Spark's potential treatment for one genetic cause of blindness, SPK-RPE65, is in the third, and typically final, phase of clinical trials, with data due in the second half of 2015. "We had plenty of interested parties, but we thought this was a unique confluence of things that presented a chance for CHOP to capitalize on the value more than it might have traditionally.". As the New York Stock Exchange celebrated the debut of Shake Shack, another lesser-known company had its IPO on the NASDAQ. Spark's pipeline also includes SPK-CHM, a treatment for the retinal disease choroideremia; and SPK-FIX, a Pfizer ($PFE)-partnered hemophilia B therapy. Spark operated from Children's offices until September, when it moved to the University City Science Center on Market Street. Spark nails a $161M IPO to fund its 'breakthrough' gene therapy. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Get instant access to a free live streaming chart of the Spark Therapeutics Inc Stock. Last year, biotech debutantes raised a record $6.3 billion in IPO cash, a figure buoyed by increasing high valuations and investor fervor over new technologies. Spark has set aside another 1 million shares for its underwriters, putting it in line to gross about $185 million if they exercise their options. All of the shares in the offering are being sold by Spark. Spark Therapeutics Quote & Chart - Click for current quote - ONCE About Spark Therapeutics (adapted from Spark Therapeutics prospectus): As drugmaker Gilead has learned with its high-priced cure for hepatitis C, that's not always easy. ; Pussinen will … Besides the cash, the reputation of the hospital and its researchers lent the new enterprise "leverage" when it sought other investors and secondary licensing deals, chief executive officer Jeffrey D. Marrazzo said. Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. The two best deals of the week are thought to be Spark... Pfizer, Inc. (NYSE:PFE), Spark Therapeutics (NASDAQ:ONCE) - What You Need To Know About The Spark Therapeutics IPO | … Roche Group (OTCQX:RHHBY) company Spark Therapeutics announces the appointment of biopharma industry veteran Cynthia Pussinen as its chief technical officer. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Enclose phrases in quotes. With about 50 employees now, Spark agreed to create 67 jobs in exchange for a $150,000 state grant and $201,000 in job-creation tax credits. Spark Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Spark's approach to gene therapy involves targeting diseases that result from genetic malfunctions and using a modified version the harmless adeno-associated virus (AAV) to deliver corrective genes. 가격,차트,기술적 분석,실적 자료,Spark Therapeutics Inc 보고서와 그이외를 포함한 Spark Therapeutics Inc 주식에 대한 자세한 정보를 얻으십시오. Spark Therapeutics Inc is a United States based company operating in the field of gene therapy. In its S-1 filing with the Securities and Exchange Commission, Spark said it had applied to trade on the Nasdaq global market under the symbol "ONCE."